Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

Perjeta (pertuzumab) is already available for use in HER-2 positive patients with metastatic breast cancer when combined with Herceptin and docetaxel, but is only available through the Cancer ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...